The US Food and Drug Administration (FDA) has granted another approval for Dupixent (dupilumab), for the treatment of adults and adolescents aged 12 years and older with chronic spontaneous urticaria (CSU) who remain symptomatic despite histamine-1 (H1) antihistamine treatment.
This is the latest indication for French pharma major Sanofi’s (Euronext: SAN) blockbuster Dupixent, for which global net sales reached around 13.1 billion euros ($14.1 billion) last year, marking a 23% year-over-year increase, with analysts projecting annual revenue to exceed 20 billion euros by 2030, before patent expiration and biosimilar competition kick in.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2025 | Headless Content Management with Blaze